Senti Biosciences, Inc.SNTIEarnings & Financial Report
Senti Biosciences, Inc. is a clinical-stage biotechnology company specializing in synthetic biology and gene circuit engineering to develop next-generation programmable cell and gene therapies. Its core pipeline targets oncology and autoimmune diseases, serving global biopharmaceutical markets and partnering with leading industry players to advance targeted treatments for underserved patient groups.
SNTI Q2 FY2025 Key Financial Metrics
Revenue
$1.8M
Gross Profit
N/A
Operating Profit
$-16.8M
Net Profit
$-14.7M
Gross Margin
N/A
Operating Margin
-936.3%
Net Margin
-821.2%
YoY Growth
N/A
EPS
$-0.56
Senti Biosciences, Inc. Q2 FY2025 Financial Summary
Senti Biosciences, Inc. reported revenue of $1.8M for Q2 FY2025, with a net profit of $-14.7M (down 31.5% YoY) (-821.2% margin).
Key Financial Metrics
| Total Revenue | $1.8M |
|---|---|
| Net Profit | $-14.7M |
| Gross Margin | N/A |
| Operating Margin | -936.3% |
| Report Period | Q2 FY2025 |
Senti Biosciences, Inc. Annual Revenue by Year
Senti Biosciences, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $0).
Senti Biosciences, Inc. Quarterly Revenue & Net Profit History
Senti Biosciences, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q2 FY2025 | $1.8M | — | $-14.7M | -821.2% |
| Q1 FY2025 | $1.9M | — | $-14.1M | -746.3% |
| Q4 FY2024 | $0 | — | $-610.0K | N/A |
| Q3 FY2024 | $0 | — | $-28.9M | N/A |
| Q2 FY2024 | $0 | — | $-11.2M | N/A |
| Q1 FY2024 | $0 | — | $-12.1M | N/A |
| Q4 FY2023 | $0 | — | $-18.7M | N/A |
| Q3 FY2023 | $255.0K | -83.2% | $-14.9M | -5852.2% |
Income Statement
| Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $255000 | $0 | $0 | $0 | $0 | $0 | $1.9M | $1.8M |
| YoY Growth | -83.2% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Balance Sheet
| Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $131.8M | $119.5M | $102.2M | $86.9M | $57.7M | $97.8M | $82.8M | $68.5M |
| Liabilities | $48.8M | $52.6M | $46.1M | $42.8M | $41.7M | $47.1M | $44.9M | $43.9M |
| Equity | $82.9M | $66.9M | $56.1M | $44.1M | $16.0M | $25.6M | $37.9M | $24.7M |
Cash Flow
| Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-15.4M | $-7.0M | $-11.7M | $-8.3M | $-7.9M | $-13.5M | $-14.1M | $-13.1M |